|
| 37147690 | Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. | Crit Care | 2023 |
| 30279233 | A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. | Clin Cancer Res | 2019 |
| 30810837 | [The German keratomycosis registry : Initial results of a multicenter survey]. | Ophthalmologe | 2019 |
| 30768522 | The authors reply. | Crit Care Med | 2019 |
| 30553989 | Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data. | J Crit Care | 2019 |
| 29509568 | Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. | Crit Care Med | 2018 |
| 29415215 | Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study. | Neuro Oncol | 2018 |
| 28528561 | Angiotensin II for the Treatment of Vasodilatory Shock. | N Engl J Med | 2017 |
| 28651927 | Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. | Lancet Oncol | 2017 |
| 27169385 | Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia. | Am J Hematol | 2016 |
| 25512461 | Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. | J Clin Oncol | 2015 |
| 25185097 | Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. | J Clin Oncol | 2014 |
| 23228990 | A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. | Cancer Chemother Pharmacol | 2013 |
| 21415214 | Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. | Clin Cancer Res | 2011 |
| 25386307 | Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302. | Dermatol Reports | 2011 |
| 21625179 | A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. | Oncology | 2011 |
| 19687729 | A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma. | Am J Clin Oncol | 2010 |
| 19188061 | A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. | Eur J Cancer | 2009 |
| 17661038 | A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. | Cancer Chemother Pharmacol | 2008 |
| 17325895 | Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement. | Leuk Lymphoma | 2007 |
| 15689582 | 131I-tositumomab therapy as initial treatment for follicular lymphoma. | N Engl J Med | 2005 |
| 16204016 | Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. | J Clin Oncol | 2005 |
| 16186600 | Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. | J Clin Oncol | 2005 |
| 16331761 | A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis. | J Rheumatol | 2005 |
| 16110029 | Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. | J Clin Oncol | 2005 |
| 15613695 | Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. | J Clin Oncol | 2005 |
| 15731177 | Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. | Blood | 2005 |
| 15084620 | Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. | J Clin Oncol | 2004 |
| 15585610 | The radioisotope contributes significantly to the activity of radioimmunotherapy. | Clin Cancer Res | 2004 |
| 12610191 | Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. | J Clin Oncol | 2003 |
| 11877754 | Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy. Conjugate views compared with a hybrid method. | Cancer | 2002 |
| 12359605 | Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy. | Ophthalmology | 2002 |
| 11884495 | A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy. | J Nucl Med | 2002 |
| 11579112 | Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. | J Clin Oncol | 2001 |
| 10942366 | Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. | Blood | 2000 |
| 10334351 | Randomized trial of radiation for age-related macular degeneration. | Am J Ophthalmol | 1999 |
| 9818602 | A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma. | Ophthalmology | 1998 |
| 9437317 | Ten-year follow-up of helium ion therapy for uveal melanoma. | Am J Ophthalmol | 1998 |
| 9612598 | Candidates for prostate radioactive seed implantation treated by external beam radiotherapy. | Cancer J Sci Am | 1998 |
| 9708567 | Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. | J Nucl Med | 1998 |
| 9708566 | Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. | J Nucl Med | 1998 |
| 9392537 | Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma. | Int J Radiat Oncol Biol Phys | 1997 |
| 9227204 | Orbital metastases: diagnosis and course. | Br J Ophthalmol | 1997 |
| 9263801 | Adjuvant electron-beam IORT in high-risk head and neck cancer patients. | Front Radiat Ther Oncol | 1997 |
| 9169803 | Prognostic factors in adult soft-tissue sarcomas of the head and neck. | Int J Radiat Oncol Biol Phys | 1997 |
| 9258223 | Uveal melanoma. Growth rate and prognosis. | Arch Ophthalmol | 1997 |
| 9135379 | Retinal detachment in AIDS: long-term results after repair with silicone oil. | Br J Ophthalmol | 1997 |
| 9373108 | Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma. | Ophthalmology | 1997 |
| 9300746 | Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. | Int J Radiat Oncol Biol Phys | 1997 |
| 9440169 | Long-term follow-up after uveal melanoma charged particle therapy. | Trans Am Ophthalmol Soc | 1997 |